Effect of the second and third COVID-19 pandemic waves on routine outpatient malaria indicators and case management practices in Uganda: an interrupted time series analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101139802 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2875 (Electronic) Linking ISSN: 14752875 NLM ISO Abbreviation: Malar J Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2002-
    • Subject Terms:
      COVID-19*/epidemiology ; COVID-19*/diagnosis ; Malaria*/drug therapy ; Malaria*/diagnosis ; Malaria*/epidemiology ; Interrupted Time Series Analysis* ; Case Management*/statistics & numerical data; Uganda/epidemiology ; Humans ; Adult ; Female ; Male ; SARS-CoV-2 ; Outpatients/statistics & numerical data ; Artemether, Lumefantrine Drug Combination/therapeutic use ; Antimalarials/therapeutic use ; Adolescent ; Middle Aged ; Child ; Young Adult ; Ambulatory Care/statistics & numerical data ; Child, Preschool
    • Abstract:
      Background: Reports on the impact of COVID-19 pandemic on the quality of malaria care and burden in sub Saharan Africa have provided a mixed picture to date. The impact of the 2nd (Delta) and 3rd (Omicron) COVID-19 waves on outpatient malaria indicators and case management practices was assessed at three public health facilities with varying malaria transmission intensities in Uganda.
      Methods: Individual level data from all patients presenting to the out-patient departments (OPD) of the three facilities (Kasambya, Walukuba and Lumino) between January 2019 and February 2022 were included in the analysis. Outcomes of interest included total number of outpatient (OPD) visits, proportion of patients suspected to have malaria, proportion of suspected malaria cases tested with a malaria diagnostic test, test positivity rates (TPR) and proportion of malaria cases prescribed artemether-lumefantrine (AL). Using the pre-COVID-19 trends between January 2019 and February 2020, interrupted time series analysis was used to predict the expected trends for these study outcomes during the 2nd wave (May 2021-August 2021) and 3rd wave (November 2021-February 2022). The observed trends of the study outcomes were compared with the expected trends.
      Results: There were no significant differences between the observed versus expected overall outpatient visits in the 2nd wave, however, a significant decline in OPD attendance was observed during the 3rd wave (15,101 vs 31,154; incidence rate ratio (IRR) = 0.48 [0.41-0.56]). No significant differences in the overall observed versus expected proportions of suspected malaria cases and test positivity rates in both COVID waves. However, a significant decrease in the overall proportion of suspected malaria cases tested with a malaria diagnostic test was observed during the 3rd wave (99.86% vs 99.99%; relative percent ratio [RPR] = 0.99 [0.99-0.99]). Finally, a significant decline in the overall proportion of malaria cases prescribed AL was observed during the 2nd wave (94.99% vs 99.85%; RPR = 0.95 [0.92-0.98]) but not the 3rd wave.
      Conclusion: Significant declines in OPD attendance and suspected malaria cases tested with malaria diagnostic test were observed during the 3rd COVID-19 wave, while AL prescription significantly reduced during the 2nd COVID-19 wave. These findings add to the body of knowledge highlighting the adverse impact of COVID-19 pandemic on the malaria which could explain the increase in the malaria burden observed during this period.
      (© 2024. The Author(s).)
    • References:
      World Dev. 2021 Apr;140:105318. (PMID: 34548741)
      Int J Health Sci (Qassim). 2020 May-Jun;14(3):7-8. (PMID: 32536842)
      Trop Med Infect Dis. 2023 Apr 04;8(4):. (PMID: 37104342)
      Int J Environ Res Public Health. 2022 Mar 16;19(6):. (PMID: 35329229)
      Am J Trop Med Hyg. 2021 Jan;104(1):26-29. (PMID: 33205743)
      Malar J. 2023 Mar 06;22(1):78. (PMID: 36872343)
      PLOS Glob Public Health. 2023 May 19;3(5):e0001881. (PMID: 37205645)
      Malar J. 2020 Dec 23;19(1):457. (PMID: 33357220)
      Pan Afr Med J. 2020 May 27;35(Suppl 2):51. (PMID: 33623576)
      Open Forum Infect Dis. 2021 Nov 18;8(11):ofab530. (PMID: 34805440)
      Malar J. 2021 May 24;20(1):233. (PMID: 34030711)
      Malar J. 2021 Dec 20;20(1):475. (PMID: 34930317)
      Am J Trop Med Hyg. 2006 Aug;75(2):219-25. (PMID: 16896122)
      Malar J. 2022 May 15;21(1):149. (PMID: 35570272)
      Malar J. 2022 Dec 19;21(1):388. (PMID: 36536428)
      Pan Afr Med J. 2021 Mar 11;38:254. (PMID: 34104302)
      Korean J Parasitol. 2021 Aug;59(4):399-402. (PMID: 34470091)
      BMJ Glob Health. 2020 Sep;5(9):. (PMID: 32938611)
      PLoS One. 2022 Dec 30;17(12):e0279464. (PMID: 36584122)
      Lancet Infect Dis. 2021 Jan;21(1):59-69. (PMID: 32971006)
      Malar J. 2022 Feb 14;21(1):48. (PMID: 35164781)
      BMJ Open. 2022 Apr 22;12(4):e051015. (PMID: 35459661)
      PLOS Glob Public Health. 2022 Sep 7;2(9):e0000676. (PMID: 36962736)
    • Contributed Indexing:
      Keywords: COVID-19 pandemic; COVID19-wave; Interrupted time series analysis; Malaria; Malaria case management; Outpatient Department; Routine outpatient malaria indicators; Uganda
    • Accession Number:
      0 (Artemether, Lumefantrine Drug Combination)
      0 (Antimalarials)
    • Publication Date:
      Date Created: 20241030 Date Completed: 20241030 Latest Revision: 20241101
    • Publication Date:
      20241101
    • Accession Number:
      PMC11520443
    • Accession Number:
      10.1186/s12936-024-05153-0
    • Accession Number:
      39472901